Bausch Health Companies BHC International — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch Health Companies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bausch Health Companies's international — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bausch Health Companies's international — R&D?
- Bausch Health Companies (BHC) reported international — R&D of $6M in Q1 2026.
- How has Bausch Health Companies's international — R&D changed year-over-year?
- Bausch Health Companies's international — R&D decreased by 0.0% year-over-year, from $6M to $6M.
- What is the long-term trend for Bausch Health Companies's international — R&D?
- Over 3 years (2022 to 2025), Bausch Health Companies's international — R&D has grown at a 7.1% compound annual growth rate (CAGR), from $22M to $27M.
- What does international — R&D mean?
- Represents the expenditures dedicated to the discovery, clinical development, and regulatory approval of new products specifically for the international market. This investment is crucial for maintaining a competitive product pipeline and ensuring long-term growth. It reflects the company's commitment to innovation within its international portfolio.